title: Placental Protein 13 Administration to Pregnant Rats Lowers Blood Pressure and Augments Fetal Growth and Venous Remodeling.
abstract: Reduced first-trimester concentrations of placental protein 13 (PP13) are associated with subsequent development of preeclampsia, a major pregnancy disorder. We previously showed that PP13 has a vasodilatory effect, reduces blood pressure and augments expansive remodeling of the uteroplacental vasculature in pregnant rats. In this study, slow-release osmotic pumps were implanted in gravid rats (on day 8) to provide 1 week of PP13 supplementation. Treatment was associated with a reversible blood pressure reduction that returned to normal on day 15. In addition, PP13 caused venous expansion that is larger in the venous branches closer to the placenta. Then, it increased placental and pup weights. Similar administration of a truncated PP13 variant (DelT221) that is unable to bind carbohydrates (a rare spontaneous mutation associated with a high frequency of severe early preeclampsia among Blacks in South Africa) produced a hypotensive effect similar to the full-length molecule, but without venous remodeling and increased placental and pup weights. These results indicate the importance of PP13 carbohydrate binding for inducing vascular remodeling and improving reproductive outcome. Future studies are needed to determine whether beneficial effects would be evident in animal models of preeclampsia or in women predisposed to the development of preeclampsia.
authors: Faculty of Pharmaceutical Sciences, School of Health Science, University of Iceland, Reykjavik, Iceland.
authors: Sveinbjorn
authors: S
authors: Gizurarson
authors: Elisabet Run
authors: ER
authors: Sigurdardottir
authors: Hamutal
authors: H
authors: Meiri
authors: Berthold
authors: B
authors: Huppertz
authors: Marei
authors: M
authors: Sammar
authors: Adi
authors: A
authors: Sharabi-Nov
authors: Maurizio
authors: M
authors: Mandalá
authors: George
authors: G
authors: Osol
mesh_terms: D000818:Animals; D001724:Birth Weight / Q000187:drug effects*; D001794:Blood Pressure / Q000187:drug effects; D004353:Drug Evaluation, Preclinical; D005260:Female; D047109:Fetal Development / Q000187:drug effects; D037161:Galectins / Q000235:genetics / Q000494:pharmacology* / Q000627:therapeutic use; D008098:Litter Size / Q000187:drug effects; D010920:Placenta / Q000187:drug effects; D011225:Pre-Eclampsia / Q000188:drug therapy / Q000235:genetics*; D011247:Pregnancy; D011257:Pregnancy Proteins / Q000235:genetics / Q000494:pharmacology* / Q000627:therapeutic use; D017207:Rats, Sprague-Dawley; D014599:Uterus / Q000098:blood supply / Q000187:drug effects*; D066253:Vascular Remodeling / Q000187:drug effects*
chemical_list: D037161:Galectins; D011257:Pregnancy Proteins; C000611891:placental protein 13, rat